Pinetree Therapeutics Raises $47M in Series B

Why It Matters

The infusion of $47 million accelerates Pinetree’s path toward clinical trials, potentially delivering novel therapies for hard‑to‑treat cancers and positioning the company as a key player in the rapidly expanding protein‑degrader market.

Deal Summary

Pinetree Therapeutics, a Cambridge-based preclinical biotech focused on targeted protein degraders for drug-resistant cancers, closed a $47M Series B financing. The round included participation from existing backers DSC Investment, WIDWIN Investment, STIC Ventures, Samho Green Investment, Atinum Investment, S&S Investment, SJ Investment Partners, Smilegate Investment, Gauss Capital Management and new investor Korea Investment Partners.